Florbetapir (marketed as Amyvid, also known as 18F-AV-45 or florbetapir F18) is an FDA-approved amyloid positron emission tomography (PET) imaging agent designed to detect beta-amyloid (Aβ) plaques in the brains of individuals with Alzheimer's disease (AD) and other cognitive disorders[@clark2012]. Approved by the US Food and Drug Administration in 2012, florbetapir was the first 18F-labeled amyloid PET tracer to receive regulatory approval, representing a significant advancement in the in-vivo assessment of Alzheimer's disease neuropathology[@carroll2013].
The development of florbetapir built upon the foundational work with Pittsburgh Compound B (PiB), the first-generation amyloid PET ligand developed in the early 2000s[@klunk1998]. While PiB revolutionized amyloid imaging research, its reliance on carbon-11 (half-life 20 minutes) limited practical clinical application. Florbetapir substituted fluorine-18 (half-life 110 minutes), enabling broader distribution from centralized production facilities and more flexible imaging protocols, making amyloid PET feasible for routine clinical practice[@wong2010].
Florbetapir (marketed as Amyvid, also known as 18F-AV-45 or florbetapir F18) is an FDA-approved amyloid positron emission tomography (PET) imaging agent designed to detect beta-amyloid (Aβ) plaques in the brains of individuals with Alzheimer's disease (AD) and other cognitive disorders[@clark2012]. Approved by the US Food and Drug Administration in 2012, florbetapir was the first 18F-labeled amyloid PET tracer to receive regulatory approval, representing a significant advancement in the in-vivo assessment of Alzheimer's disease neuropathology[@carroll2013].
The development of florbetapir built upon the foundational work with Pittsburgh Compound B (PiB), the first-generation amyloid PET ligand developed in the early 2000s[@klunk1998]. While PiB revolutionized amyloid imaging research, its reliance on carbon-11 (half-life 20 minutes) limited practical clinical application. Florbetapir substituted fluorine-18 (half-life 110 minutes), enabling broader distribution from centralized production facilities and more flexible imaging protocols, making amyloid PET feasible for routine clinical practice[@wong2010].
The tracer binds with high affinity to fibrillar Aβ plaques, allowing visualization and quantification of amyloid burden in cortical brain regions characteristic of Alzheimer's disease pathology. Unlike cerebrospinal fluid biomarkers that reflect molecular signatures in the periphery, florbetapir PET provides direct spatial mapping of amyloid deposition in the living brain, enabling clinicians and researchers to assess disease stage, differential diagnosis, and treatment response[@wolk2011].
Florbetapir is a stilbene derivative with a molecular formula of C20H19FN2O3. The chemical structure features a 2-phenylbenzothiazole core that confers high affinity for aggregated Aβ plaques. The key structural element is the 4-(N-methylamino)phenyl substituent at the 2-position of the stilbene backbone, which enhances brain uptake and binding specificity[@joshi2012].
The tracer contains a single fluorine-18 radioisotope, introduced via electrophilic substitution at the aromatic ring. The 18F label produces positrons with a maximum energy of 0.633 MeV, resulting in PET images with spatial resolution suitable for cortical imaging. The half-life of 110 minutes allows for centralized production and distribution to multiple imaging centers within a regional network[@joshi2012].
Florbetapir demonstrates favorable radiopharmaceutical properties for amyloid PET imaging:
| Property | Value | Clinical Significance |
|----------|-------|----------------------|
| Radiochemical purity | >95% | Ensures specific signal |
| Specific activity | >50 GBq/μmol | Enables low mass dose |
| Brain uptake (SUV) | 4-6 at 10 min | Adequate for imaging |
| White matter binding | Moderate | Can affect quantification |
| Blood-brain barrier penetration | High | Good target-to-background |
The tracer demonstrates rapid brain uptake with peak concentrations achieved within 5-10 minutes after intravenous injection. This rapid kinetics allows for early imaging, reducing overall scanning time and improving patient throughput compared to later-imaging tracers[@wong2010].
Florbetapir binds selectively to fibrillar Aβ plaques through hydrophobic interactions with the beta-sheet secondary structure that characterizes amyloid fibrils[@joshi2012]. The binding site appears to be distinct from that of some other amyloid ligands, with high affinity for the aggregated form of Aβ while showing minimal binding to soluble oligomers or monomeric species.
The dissociation constant (Kd) for florbetapir binding to Aβ plaques has been reported in the low nanomolar range, indicating high-affinity interaction with the pathological target. Preclinical studies in transgenic mouse models of AD demonstrated clear visualization of amyloid plaques in cortical and hippocampal regions, with excellent correlation between PET signal and postmortem immunohistochemistry for Aβ[@wong2010].
After intravenous injection, florbetapir demonstrates rapid distribution to the brain, with peak uptake occurring within 5-10 minutes post-injection. The tracer shows moderate non-specific binding to white matter, which is accounted for in established quantification methods. Imaging is typically performed 30-50 minutes after injection to allow optimal signal-to-background ratios to develop while maintaining adequate counting statistics[@agost2014].
The tracer exhibits moderate washout from regions without significant amyloid deposition, while cortical regions with amyloid plaques retain the ligand, producing characteristic contrast between positive and negative scans. The relatively short imaging window (30-50 minutes post-injection) represents a practical advantage for clinical implementation compared to later-imaging tracers that require 90-120 minute waits[@agost2014].
Florbetapir PET is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD or other cognitive disorders[@clark2012]. The primary clinical utility lies in increasing diagnostic confidence, particularly in atypical presentations or when clinical features alone cannot differentiate AD from other dementia types.
A positive florbetapir scan indicates the presence of moderate to severe amyloid pathology, supporting an AD-type neurodegenerative process as the likely cause of cognitive symptoms. A negative scan suggests that AD-type amyloid pathology is unlikely to be contributing to the clinical presentation, shifting diagnostic consideration toward non-AD conditions[@johnson2013].
In the differential diagnosis of dementia, florbetapir helps distinguish AD from non-AD conditions that may present with similar clinical features[@sabri2015]. Frontotemporal lobar degeneration, vascular dementia, dementia with Lewy bodies, and primary psychiatric disorders typically show negative amyloid PET results, while AD consistently demonstrates amyloid positivity in the vast majority of cases.
The ability to rule in or rule out amyloid pathology has practical implications for patient management, including avoidance of potentially inappropriate treatments and better allocation of resources. Patients with amyloid-negative cognitive impairment may benefit from investigation of alternative causes rather than assuming an AD diagnosis[@mcgovern2014].
For patients with mild cognitive impairment (MCI), florbetapir provides important prognostic information. Multiple studies have demonstrated that amyloid-positive MCI patients have a substantially higher risk of progression to AD dementia compared to amyloid-negative MCI patients, with annualized conversion rates approximately 2-3 times higher in the amyloid-positive group[@wolk2011].
This prognostic information can be valuable for clinical counseling, care planning, and identification of appropriate candidates for clinical trials targeting AD pathology. Patients with MCI who are amyloid-positive represent an optimal target population for disease-modifying interventions that require the presence of AD-type pathology[@hatton2018].
Florbetapir PET is particularly valuable in early-onset dementia cases, where the differential diagnosis is often broader and amyloid pathology may be less predictable based on age alone. Studies have demonstrated that amyloid positivity rates in early-onset AD are high, but a subset of patients with early-onset cognitive impairment have non-AD pathology that can be identified through negative amyloid PET[@tsai2018].
Florbetapir is extensively used in AD clinical trials for patient selection and outcome assessment. Anti-amyloid therapeutic trials have required confirmation of amyloid positivity at baseline to ensure enrolled participants have the target pathology. Additionally, florbetapir PET has served as an outcome measure to demonstrate amyloid reduction in response to treatment[@salloway2016].
The tracer has been utilized in studies of monoclonal antibodies targeting Aβ, including bapineuzumab, solanezumab, and donanemab, providing evidence of target engagement and biological activity in early-phase trials that informed late-phase development decisions. Florbetapir has also been used to demonstrate amyloid removal in response to gamma-secretase and BACE inhibitors in development[@landau2016].
Large-scale validation studies have established the diagnostic accuracy of florbetapir PET for detection of amyloid pathology. In the pivotal phase III study, florbetapir demonstrated sensitivity of 96% and specificity of 83% for detection of moderate to frequent amyloid plaques on postmortem neuropathological examination[@clark2012]. These performance characteristics meet the standards for clinically useful diagnostic tests.
Florbetapir PET signal correlates strongly with postmortem measures of amyloid burden. Studies examining brain tissue from individuals who underwent PET imaging before death demonstrated significant correlations between in-vivo SUVR measurements and quantitative measures of amyloid plaque density from neuropathological examination. This validation is critical for establishing the biological validity of the imaging measure[@sabri2015].
Florbetapir shows high concordance with other FDA-approved amyloid PET tracers, particularly Pittsburgh Compound B (PiB) and flutemetamol. Direct comparison studies have demonstrated correlation coefficients exceeding 0.90 between florbetapir and PiB, suggesting that these tracers provide comparable information about amyloid burden despite different chemical structures and kinetic properties[@rowe2015].
The main practical differences between tracers relate to imaging timing (florbetapir: 30-50 min; flutemetamol/florbetaben: 90-120 min) and non-specific white matter binding characteristics. The choice between tracers often depends on scanner availability and center experience rather than diagnostic performance differences[@pontecorvo2015].
Quantitative assessment of florbetapir PET typically employs standardized uptake value ratio (SUVR) methodology, normalizing regional uptake to a reference region lacking significant amyloid binding[@agost2014]. The cerebellar cortex or pons is commonly used as reference regions, with SUVR calculated for cortical regions known to accumulate amyloid in AD, including prefrontal, posterior cingulate, lateral temporal, and parietal cortices.
Key cortical regions of interest for florbetapir quantification include the prefrontal cortex, lateral temporal cortex, posterior cingulate cortex, and parietal cortex. These regions consistently show elevated uptake in amyloid-positive individuals and provide robust discrimination between AD and control populations[@lewitt2018]. The specific regions included and their relative weighting may vary across studies and clinical protocols.
Established SUVR cutoffs have been validated for clinical interpretation, typically ranging from 1.1 to 1.2 depending on the specific quantification method and population[@bullich2017]. Values above the cutoff are classified as amyloid-positive, while values below indicate amyloid-negative status. These cutoffs demonstrate high agreement with visual reading by trained interpreters and with neuropathological assessment of amyloid at autopsy.
Florbetapir uptake follows the characteristic pattern of amyloid deposition in AD, with early involvement of posterior cingulate and prefrontal regions, progressing to lateral temporal and parietal cortices as disease advances[@lewitt2018]. Distinct spatial patterns may provide information beyond simple binary classification, with some studies suggesting that regional distribution patterns can help predict clinical progression rates or distinguish between typical and atypical AD phenotypes.
Appropriate use criteria for amyloid PET, including florbetapir, have been established by professional societies to guide appropriate clinical utilization[@johnson2013]. Recommended clinical scenarios include:
Standard florbetapir PET scanning involves intravenous injection of approximately 370 MBq (10 mCi) of radiotracer, with PET acquisition beginning approximately 30-50 minutes after injection[@schmidt2015]. Image acquisition typically lasts 10-20 minutes and may be performed as a single static acquisition or as a dynamic protocol for more detailed kinetic analysis in research settings.
Visual interpretation of florbetapir scans requires training and experience, with established patterns of positive and negative findings. Positive scans show increased uptake in cortical regions relative to white matter, with characteristic sparing of the sensorimotor cortex and subcortical structures. Negative scans demonstrate uniform uptake with no focal cortical elevations beyond background levels[@johnson2013].
Florbetapir has demonstrated an excellent safety profile in clinical trials and post-marketing experience. Across more than 1,000 subjects evaluated in clinical trials, adverse events were uncommon and typically mild in severity. The most frequently reported adverse events included headache, fatigue, and injection site reactions, occurring in less than 2% of participants[@schmidt2015].
No serious adverse events attributed to florbetapir have been reported in large clinical series. The tracer does not appear to interact with commonly prescribed medications or to produce physiological effects beyond the radiation exposure from the radioisotope.
The effective radiation dose from a standard florbetapir PET scan is approximately 6-7 mSv, comparable to other diagnostic nuclear medicine procedures and similar to other amyloid PET tracers. This radiation dose is considered acceptable for clinical diagnostic use and is justified when the information obtained will influence important clinical management decisions[@schmidt2015].
Florbetapir is contraindicated in patients with known hypersensitivity to the tracer. Standard precautions for PET imaging apply, including caution in pregnant patients due to fetal radiation exposure and recommendation to discontinue breastfeeding for 24 hours after injection due to potential excretion in breast milk.
Florbetapir can detect amyloid pathology in cognitively normal individuals with preclinical AD, years before clinical symptoms manifest[@hatton2018]. This capability has important implications for prevention trials targeting individuals at risk for AD and for understanding the temporal sequence of AD pathological changes. Approximately 10-30% of cognitively normal older adults show amyloid positivity, representing a target population for preventive interventions.
Florbetapir PET has been applied in individuals with Down syndrome, who have very high rates of AD amyloid pathology by midlife due to chromosome 21 trisomy containing the APP gene. Studies in these populations have provided insights into the earliest manifestations of amyloid deposition and the relationship between amyloid and clinical outcomes in this high-risk population[@collins2019].
Florbetapir PET is valuable in atypical presentations of AD, including posterior cortical atrophy, logopenic aphasia, and corticobasal syndrome. While clinical phenotypes may differ, amyloid positivity supports underlying AD pathology even when typical amnestic features are absent[@knight2016].
While florbetapir reliably detects Aβ plaques, it does not provide information about other key AD pathologies, including tau neurofibrillary tangles and neurodegeneration. The AT(N) biomarker framework emphasizes that comprehensive assessment requires multiple biomarker modalities to fully characterize AD pathological changes.
Many elderly individuals with dementia have mixed pathology, including both AD and vascular changes or other neurodegenerative processes. Florbetapir PET cannot distinguish between pure AD and mixed presentations, requiring integration with other clinical and imaging information for accurate diagnosis.
Cerebral amyloid angiopathy (CAA) involves Aβ deposition in cerebral blood vessels rather than parenchymal plaques. Florbetapir can show positivity in CAA, which may confound interpretation in some cases. The relationship between amyloid PET and CAA remains an area of active investigation.
Amyloid PET remains expensive and not universally accessible, limiting widespread clinical implementation. Access is concentrated in major academic medical centers and specialized memory clinics, creating disparities in availability across geographic regions and healthcare systems.
Florbetapir PET studies have established relationships between amyloid burden and other AD biomarkers, including cerebrospinal fluid Aβ42 levels, tau biomarkers, and neurodegeneration markers. These biomarker correlations support the conceptual framework of AD as a biological construct defined by specific pathological processes that can be measured in living individuals.
Beyond clinical diagnosis, florbetapir PET enables detailed mapping of amyloid burden across brain regions, supporting research into the spatial progression of AD pathology. Longitudinal studies have characterized changes in amyloid burden over time, demonstrating that amyloid accumulation plateaus in later disease stages while neurodegeneration continues to progress.
The pharmaceutical industry has relied extensively on florbetapir PET for AD drug development. Amyloid PET has been used to demonstrate target engagement for anti-amyloid antibodies, to select appropriate patient populations for clinical trials, and to provide supporting evidence for regulatory approval of disease-modifying therapies. The availability of amyloid PET has transformed AD clinical research from a purely clinical phenotype-based approach to a biologically informed framework.
Research is ongoing to combine florbetapir PET with tau PET imaging to provide more complete characterization of AD pathology in vivo. The combination of amyloid and tau PET offers the possibility of stage-based classification that aligns with emerging therapeutic strategies targeting both pathologies.
Automated quantification methods and machine learning approaches are being developed to improve the precision and reproducibility of florbetapir PET analysis. These technical advances may enable more sensitive detection of subtle changes over time and better integration with clinical outcomes in research settings.
As anti-amyloid therapies become clinically available, florbetapir PET may serve as a companion diagnostic to verify target engagement and to monitor amyloid lowering in response to treatment. This application represents an important frontier for precision medicine in AD management.
Florbetapir is closely related to other amyloid biomarkers in the NeuroWiki: